Cargando…

Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

BACKGROUND: Response to modern treatment strategies, which combine cytotoxic compounds with immune stimulatory agents and targeted treatment is highly variable among MCL patients. Thus, providing prognostic and predictive markers for risk adapted therapy is warranted and molecular information that c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lokhande, Lavanya, Kuci Emruli, Venera, Kolstad, Arne, Hutchings, Martin, Räty, Riikka, Jerkeman, Mats, Ek, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720632/ https://www.ncbi.nlm.nih.gov/pubmed/33287742 http://dx.doi.org/10.1186/s12885-020-07678-4

Ejemplares similares

Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma
por: Lokhande, Lavanya, et al.
Publicado: (2021)

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
por: Nikkarinen, Anna, et al.
Publicado: (2023)

Identification of V-ATPase as a molecular sensor of SOX11-levels and potential therapeutic target for mantle cell lymphoma
por: Emruli, Venera Kuci, et al.
Publicado: (2016)

p53 is associated with high‐risk and pinpoints TP53 missense mutations in mantle cell lymphoma
por: Rodrigues, Joana M., et al.
Publicado: (2020)

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study
por: Nordström, Lena, et al.
Publicado: (2014)

Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established high-risk factors
por: Gerdtsson, Anna Sandström, et al.
Publicado: (2022)

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
por: Freiburghaus, Catja, et al.
Publicado: (2018)

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3
por: Eskelund, Christian Winther, et al.
Publicado: (2020)

Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma
por: Merrien, Magali, et al.
Publicado: (2021)

Tackling Mantle Cell Lymphoma in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
por: Ekberg, Sara, et al.
Publicado: (2022)

Mantle Cell Lymphoma Relapsing at the Lymphedematous Arm
por: Massini, Giuseppina, et al.
Publicado: (2013)

Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study
por: Morello, Lucia, et al.
Publicado: (2019)

Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCLcomplete Project
por: Jerkeman, Mats, et al.
Publicado: (2023)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
por: Kirschey, Sebastian, et al.
Publicado: (2012)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Relapsed Mantle Cell Lymphoma Presenting as “Sister Mary Joseph Nodule”
por: Vaughn, Jennifer E., et al.
Publicado: (2010)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
por: Aydilek, Enver, et al.
Publicado: (2023)

A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
por: Ljungars, A., et al.
Publicado: (2018)

Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
por: Borgerding, Andrea, et al.
Publicado: (2009)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
por: Bond, David A, et al.
Publicado: (2021)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
por: Bock, A., et al.
Publicado: (2022)

CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
por: Vu, Khoan, et al.
Publicado: (2022)

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023)

Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017
por: Albertsson-Lindblad, Alexandra, et al.
Publicado: (2021)

Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
por: Harrysson, Sara, et al.
Publicado: (2021)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

Treatment Outcomes and Survival Patterns of Asian Patients With Relapsed/Refractory Mantle Cell Lymphoma
por: Tan, Jing Yuan, et al.
Publicado: (2021)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
por: Heini, Alexander D., et al.
Publicado: (2022)

Relapsed mantle cell lymphoma presenting with lactic acidosis and hypoglycemia: A case report
por: Carson, Lucy, et al.
Publicado: (2023)

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2022)

Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)
por: Scheubeck, Gabriel, et al.
Publicado: (2023)

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
por: Ferrero, Simone, et al.
Publicado: (2020)

Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations
por: Wu, Chenglin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bfvt8o6s9d4h04ovgk4u78j652